Illumina, Inc. $ILMN Shares Sold by Mutual of America Capital Management LLC

Mutual of America Capital Management LLC decreased its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 9.8% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 70,983 shares of the life sciences company’s stock after selling 7,740 shares during the period. Mutual of America Capital Management LLC’s holdings in Illumina were worth $6,741,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently added to or reduced their stakes in ILMN. Cullen Frost Bankers Inc. grew its position in Illumina by 130.7% in the 3rd quarter. Cullen Frost Bankers Inc. now owns 992 shares of the life sciences company’s stock worth $94,000 after purchasing an additional 562 shares during the last quarter. Sagespring Wealth Partners LLC bought a new stake in Illumina during the third quarter worth approximately $201,000. UniSuper Management Pty Ltd boosted its stake in shares of Illumina by 73.5% during the 3rd quarter. UniSuper Management Pty Ltd now owns 4,685 shares of the life sciences company’s stock worth $445,000 after acquiring an additional 1,985 shares in the last quarter. iA Global Asset Management Inc. purchased a new position in Illumina in the 3rd quarter worth about $1,177,000. Finally, Olympiad Research LP raised its holdings in shares of Illumina by 20.0% during the third quarter. Olympiad Research LP now owns 2,770 shares of the life sciences company’s stock valued at $263,000 after acquiring an additional 462 shares during the period. Institutional investors and hedge funds own 89.42% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently commented on ILMN. TD Cowen restated a “hold” rating on shares of Illumina in a report on Wednesday, January 7th. Wall Street Zen raised Illumina from a “hold” rating to a “buy” rating in a research note on Saturday, January 17th. Robert W. Baird set a $109.00 target price on shares of Illumina in a research report on Friday, October 31st. Weiss Ratings restated a “hold (c-)” rating on shares of Illumina in a research note on Monday, December 29th. Finally, Evercore ISI reiterated an “outperform” rating and set a $155.00 target price on shares of Illumina in a research note on Monday, January 5th. Six equities research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $127.18.

Insider Buying and Selling

In other Illumina news, insider Scott M. Davies sold 323 shares of the company’s stock in a transaction on Friday, December 12th. The stock was sold at an average price of $136.09, for a total transaction of $43,957.07. Following the transaction, the insider owned 17,887 shares of the company’s stock, valued at approximately $2,434,241.83. This represents a 1.77% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Scott Gottlieb acquired 500 shares of the firm’s stock in a transaction on Monday, November 3rd. The stock was purchased at an average price of $122.13 per share, for a total transaction of $61,065.00. Following the completion of the transaction, the director directly owned 12,523 shares in the company, valued at approximately $1,529,433.99. The trade was a 4.16% increase in their position. The disclosure for this purchase is available in the SEC filing. 0.17% of the stock is currently owned by corporate insiders.

Illumina Price Performance

Shares of ILMN stock opened at $152.09 on Wednesday. Illumina, Inc. has a 52 week low of $68.70 and a 52 week high of $155.53. The stock has a market capitalization of $23.24 billion, a PE ratio of 34.10, a PEG ratio of 2.53 and a beta of 1.41. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.12 and a current ratio of 1.43. The stock’s fifty day moving average is $136.46 and its 200-day moving average is $114.09.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Thursday, October 30th. The life sciences company reported $1.34 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.16 by $0.18. Illumina had a return on equity of 29.21% and a net margin of 16.40%.The business had revenue of $1.08 billion during the quarter, compared to analysts’ expectations of $1.07 billion. During the same period in the previous year, the business posted $1.14 earnings per share. The firm’s revenue for the quarter was up .4% compared to the same quarter last year. Illumina has set its FY 2025 guidance at 4.650-4.750 EPS. Equities research analysts expect that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Illumina Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.